UCB SA will acquire United States-based Candid Therapeutics for up to $2.2B to expand its autoimmune disease portfolio. The deal includes a $2B upfront payment and $200M in potential future milestone payments for the biotech firm. This acquisition signals the Belgium-based firm's pivot toward high-growth immunology assets to offset upcoming patent expirations.
UCB to buy Candid Therapeutics for 2.2 billion dollars
UCB agreed to buy Candid Therapeutics for up to 2.2 billion dollars. The deal includes 2 billion upfront for the California-based autoimmune drug developer.
Xurve View
洞察:
Xurve View
### Scaling Autoimmune Portfolios UCB will pay $2B immediately to acquire the privately-held Candid Therapeutics. The agreement includes an additional $200M contingent on specific development milestones. UCB and Candid Therapeutics announced the deal late evening on May 3.











